These therapies encompass a wide range of approaches, including the targeting of variant epidermal growth factor III (EGFRvIII) and human epidermal growth factor receptor 2 (HER2) using engineered T cells, dendritic cell-based multi-peptides, dendritic cell-based vaccines, tumor-cell-generated vaccines, and natural killer cells [152]. The gene discussed is ERBB2; the disease is neoplasm.